24 March 2025
Frankfurt, Germany. ICIG Ventures, the venture capital unit of International Chemical Investors Group (ICIG), has successfully led the Series A funding round for LICIT Solutions GmbH, a pioneer in novel biocidal active substances. A syndicate of business angels led by Dr. Wolfgang Klein co-invested with ICIG Ventures in LICIT Solutions GmbH’s Series A funding round, successfully completing the first closing.
Founded in 2021 as a spin-out from the University of Tübingen, LICIT Solutions GmbH aims to revolutionize the biocidal industry with its substance Aminolipin®. This innovative compound features a novel mode of action, broad antimicrobial activity, and a low toxicity profile, making it suitable for various biocidal applications.
Dr Wolfgang Klein, the co-investor and business angel remarked: “When we saw the singular potential of LICIT, my partner Dr. Bernhard Arnold and myself together with other individuals started financing their development 15 months ago. Under the umbrella of Next Thursday, we now proudly contribute the largest aggregate share to the current round. We extend our heartfelt congratulations to the inventors, the management, and the team on their remarkable achievements and wish them continued success on an inspiring journey ahead.”
Dr Pelin Yilmaz, Investment Director at ICIG Ventures, comments: “We are thrilled to support LICIT Solutions at this pivotal stage of their growth. Their groundbreaking technology has the potential to transform the biocidal industry and set new standards in efficacy and safety.”
The proceeds from this funding round will be utilized to expand LICIT Solutions’ production capacities and accelerate the market introduction of Aminolipin® across new application areas.
This investment reflects ICIG Ventures’ commitment to empowering pioneering companies like LICIT Solutions, whose innovative technologies are set to redefine industry standards.
International Chemical Investors Group is a privately owned industrial group with a total turnover of more than €4 billion. ICIG focuses on several main platforms: Fine Chemicals under the WeylChem brand, Care Chemicals (Catexel), Chlorovinyls (Vynova), Compounds (Benvic), Hydrocarbons & Solvents (HCS Group), Superabsorbents (Stockhausen Superabsorber) and Enterprises with specialized businesses in industrial drying services, fermentation products, viscose filaments, activated carbon and wood protection chemicals. Today, the ICIG companies employ more than 7,100 people and operate more than 50 production sites in Europe, the U.S and India.
About LICIT Solutions GmbH
LICIT Solutions GmbH, founded in 2021 as a spin-out from the University of Tübingen, specializes in developing unique biocidal active substances. Their innovative product, Aminolipin®, offers a new mode of action with broad antimicrobial activity and a low toxicity profile, positioning it for various biocidal applications.
ICIG Ventures:
Pelin Yilmaz, Investment Director at ICIG Ventures Holding GmbH
Phone +49 (69) 506 999-0
Email: info @ ic-investors.com
LICIT Solutions:
Mona Lohmüller Management Assistant at LICIT Solutions GmbH
Phone: +49 174 1931410
Email: info @ licit-solutions.de
GERMANY